logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11434296 B1

PDFFull Text
Date of Patent:
Sep. 06, 2022

Filed:

Feb. 21, 2020

Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of tl1a function

Applicant:

Cedars-sinai Medical Center, Los Angeles, CA (US);

Inventors:

David Q. Shih, La Crescenta, CA (US);

Stephan R. Targan, Santa Monica, CA (US);

Dalin Li, Walnut, CA (US);

Janine Bilsborough, Simi Valley, CA (US);

Assignee:

CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US);

Attorney:

Wilson Sonsini Goodrich & Rosati

Primary Examiner:

Claire Kaufman

Int. Cl.
CPC ...
A61K 39/395 (2006.01); G01N 33/53 (2006.01); C07K 16/28 (2006.01); C12Q 1/6883 (2018.01); C07K 16/24 (2006.01); A61K 45/06 (2006.01); C12N 15/113 (2010.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/24 (2013.01); C07K 16/241 (2013.01); C07K 16/2875 (2013.01); C12N 15/1138 (2013.01); C12Q 1/6883 (2013.01); G01N 33/6869 (2013.01); C07K 2317/76 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/7155 (2013.01); G01N 2800/065 (2013.01); G01N 2800/10 (2013.01);
Abstract

The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.

Find Patent Forward Citations

Shih, David. (2022). Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of tl1a function (U.S. Patent No. 11434296). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11434296

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…